Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising alternative strategy mostly developed in the context of glioblastoma. However, there is a need for implementing immunotherapy for grade II/III gliomas, as these are the most common CNS tumors in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutoit, Valérie, Migliorini, Denis, Ranzanici, Giulia, Marinari, Eliana, Widmer, Valérie, Lobrinus, Johannes Alexander, Momjian, Shahan, Costello, Joseph, Walker, Paul R., Okada, Hideho, Weinschenk, Toni, Herold-Mende, Christel, Dietrich, Pierre-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749651/
https://www.ncbi.nlm.nih.gov/pubmed/29308320
http://dx.doi.org/10.1080/2162402X.2017.1391972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749651/
https://www.ncbi.nlm.nih.gov/pubmed/29308320
http://dx.doi.org/10.1080/2162402X.2017.1391972

Ejemplares similares